Movement Alert｜PHARMARON rises 3.03% in Regular Trading, institutional position changes and improving order outlook support sentiment

Market Focus11-12

On November 12, PHARMARON rose 3.03% intraday in Regular Trading, trading at HK$30.64, with turnover of HK$49.78 million.

The move appears tied to recent disclosures showing higher H-share long positions by several institutions, alongside stronger expectations for earnings and order recovery.

Recent filings showed UBS Group AG increased its long position ratio to 6.15%, while HSBC Holdings lifted its long position to 20.05%. Earlier disclosures also showed position increases by JPMorgan and Morgan Stanley. However, parts of these changes were linked to prime brokerage, controlled-corporation holdings, or derivative and rehypothecation arrangements rather than direct on-exchange purchases of common shares.

Fundamentally, PHARMARON reported first-three-quarter revenue of RMB12.003 billion, up 19.01% year over year, while new orders grew by more than 30%, with CDMO new orders up more than 40%. These figures have reinforced market expectations for a recovery in the CXO cycle and improved order conversion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment